Navigation Links
Beaumont Health System Launches Research Trial of Bioresorbable Heart Scaffold
Date:7/29/2013

Royal Oak, MI (PRWEB) July 29, 2013

Beaumont Health System has joined a multicenter, international research study of a new temporary heart device that helps keep an artery open following angioplasty, then is broken down and absorbed by the body.

The research will compare the effectiveness of the new “disappearing” device, the AbsorbTM Bioresorbable Vascular Scaffold made by health care company Abbott, with drug-eluting, metal stents that are commonly placed in heart arteries as a permanent implant. Absorb is referred to as a scaffold to indicate it is temporary in nature, unlike a permanent metallic stent. It is made of polylactide, a material commonly used in medical implants such as dissolving sutures.

Coronary artery stents were approved for use in the United States in 1994. Similar to a mesh tube, stents prop open a heart artery after a blockage is cleared with a procedure called angioplasty.

In angioplasty, a doctor threads a catheter, or hollow tube, into the arteries of the heart through a small incision in the groin or wrist, with a tiny balloon at its tip that, once inflated, pushes a blockage against the artery wall to open the artery and improve blood flow to the heart. Angioplasty is often followed by insertion of a stent coated with medication, called a drug-eluting stent, at the site of the blockage to keep the vessel open and prevent renarrowing. Metallic stents are a permanent implant in the wall of the artery.

"Stents have revolutionized the treatment of heart blockages by helping many patients to avoid having repeat angioplasty procedures and in some cases open-heart surgery,” says Amr Abbas, M.D., Beaumont’s director of interventional cardiology research and the study’s principal investigator. “This new bioabsorbable vascular scaffold is the latest technique in heart treatment in interventional cardiology.”

Research has shown that the support of a coronary stent is only needed for a few months after implantation while the artery wall is healing. Although researchers hoped to create a temporary scaffold that dissolved after doing its job, there were many scientific challenges. A decade ago, scientists at Abbott started development of Absorb and now Abbott is the first company in the world to begin testing a bioresorbable vascular scaffold in patients in the United States.

The Absorb™ BVS is available in Europe, Middle East and parts of Asia. It is an investigational device not available for sale in the U.S.

ABSORB III will enroll approximately 2,250 patients, the majority in the U.S.

For more information on the Beaumont study, including enrollment criteria, call Diedre Brunk, Beaumont Cardiology Research at 248-898-5580.

About Beaumont Heart & Vascular Care
Beaumont is Michigan’s, and one of the nation’s, most experienced providers of heart care, recognized on U.S. News & World Report’s 2013-14 “America’s Best Hospitals” list for cardiology and heart surgery. The Beaumont Heart and Vascular Center is a comprehensive, state-of-the-art facility that’s dedicated to the prevention, diagnosis and treatment of heart problems. Beaumont’s Ernst Cardiovascular Center offers a collaborative approach to treating and managing the most complex heart and vascular conditions, including atrial fibrillation, heart valve disease, heart failure, aortic aneurysm and dissection. The center offers low-cost, preventive heart screening for adults and high school students. Beaumont’s Ministrelli Women’s Heart Center is the first in Michigan devoted exclusively to the prevention, diagnosis, and research of heart disease in women. Find out more at http://heart.beaumont.edu/.

Read the full story at http://www.prweb.com/releases/beaumont/bioresorbable/prweb10973472.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Gulfside Dental Now Offers LUMINEERS in Beaumont, Texas
2. Gulfside Dental Celebrating Seniors Mardi Gras at Beaumont Civic Center
3. Gulfside Dental Visits First Steps Daycare in Beaumont, TX
4. Beaumont doctors call for training to reduce sudden cardiac arrest fatalities in schools
5. Beaumont Childrens Hospital pediatrician inducted into Legends of Neonatology Hall of Fame
6. Beaumont recipient of 2013 Dove Award from the Arc of Oakland County
7. Beaumont receives national green award
8. Beaumont cardiologist Kavitha Chinnaiyan, M.D., receives excellence in research award
9. Beaumont Cardiologist Kavitha Chinnaiyan, M.D., Receives Excellence in Research Award
10. Beaumont Health System Recognized as an American Heart Association Fit-Friendly Worksite
11. Beaumont Study: Nerve Stimulation Helps with Overactive Bladder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Healthcare ... for those in the fight against cancer, has produced a seminal study that ... HRA will release top-line findings in a webinar, Defining Compassionate Care Through the ...
(Date:2/23/2017)... ... , ... CALNOC, the nation’s first and only nursing quality indicators database today ... Value and Collaboration – in Seattle, WA on October 23, 2017. , Dr. Gary ... in Seattle since 2000. In addition to his role at Virginia Mason, Dr. Kaplan ...
(Date:2/23/2017)... ... 23, 2017 , ... HealthPostures, the desk for standing designer headquartered in Prior ... to the Minneapolis Home and Garden Show which is being held February 24 through ... attention is the Minneapolis Convention Center. , From its broad line of sit ...
(Date:2/22/2017)... York (PRWEB) , ... February 22, 2017 , ... ... entrance and lobby of a new healthcare contact center in Georgia, PENETRON Specialty ... One of the nation’s largest healthcare systems recently invested $51 million to purchase ...
(Date:2/22/2017)... ... February 22, 2017 , ... Stem cell therapy ... The technology is so cutting edge, in fact, the U.S. Food and Drug ... procedures. However, successful patient outcomes in certain clinical stem cell procedures have shown ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 2017 ... Research and Markets has announced the addition of the ... report to their offering. The Global Antifungal Drugs ... the next decade to reach approximately $12.8 billion by 2025. ... all the given segments on global as well as regional levels presented ...
(Date:2/23/2017)... Ga., Feb. 23, 2017  MiMedx Group, Inc. (NASDAQ: ... tissue and patent-protected processes to develop and market advanced ... Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, ... and full year ended December 31, 2016. ... Revenue is a 31% increase over full year 2015 ...
(Date:2/23/2017)... , Feb 23, 2017 Research and ... Devices Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 9.2% over the next decade ... report analyzes the market estimates and forecasts for all the given ...
Breaking Medicine Technology: